GLP-1 and Muscle Loss: What the Body-Composition Data Shows

"You'll lose muscle, not just fat" is one of the most repeated warnings about GLP-1 treatment, and it's directionally true — but the actual data is more specific and less alarming than the headline version. Here's what a dedicated body-composition substudy and a 2025 meta-analysis across multiple GLP-1 drugs actually measured.

The SURMOUNT-1 body-composition substudy

Most obesity trials measure weight on a scale and stop there. A substudy of 160 participants from the SURMOUNT-1 trial went further, using dual-energy X-ray absorptiometry (DXA) scans — the same imaging used to measure bone density and body composition clinically — at baseline and again at week 72¹. The results: tirzepatide-treated participants lost 21.3% of body weight on average, made up of a 33.9% reduction in fat mass and a 10.9% reduction in lean mass¹. Critically, the study also reported what proportion of the total weight lost was fat versus lean: "approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo"¹ — meaning the ratio of fat loss to muscle loss was essentially the same whether someone was on the drug or losing weight through diet and lifestyle alone in the placebo arm. That last point matters: a roughly 75/25 fat-to-lean split isn't a GLP-1-specific problem, it's close to what happens with intentional weight loss generally, drug or no drug.

What a broader meta-analysis found across drugs

A 2025 systematic review and network meta-analysis pooled body-composition data across multiple GLP-1 receptor agonists and co-agonists, not just tirzepatide, and found a consistent pattern: "lean mass loss comprising approximately 25% of the total weight loss" across the class². The same analysis flagged a meaningful difference between drugs, though: "Tirzepatide (15 mg weekly) and semaglutide (2.4 mg weekly) were the most effective for weight and fat mass reduction but were among the least effective in preserving lean mass," while "liraglutide... was the only GLP-1RA to achieve significant weight reduction without significantly reducing lean mass" in a statistically detectable way². In other words, the two most effective drugs for total weight loss also showed the most absolute lean-mass loss — not because they're worse drugs, but because they simply produce more total weight loss, and roughly a quarter of a bigger number is a bigger number. For a closer look at how semaglutide and the older liraglutide compare on cost and effect, see semaglutide vs liraglutide: is the older, cheaper GLP-1 worth it.

What "25% lean mass" doesn't tell you

Neither study measured strength, physical function, or whether the lean mass lost was primarily muscle versus other lean tissue (lean mass on a DXA scan includes some non-muscle tissue). Losing 25% of your weight-loss total as lean mass while losing a large amount of fat mass is not automatically the same as becoming meaningfully weaker — but neither trial tested strength outcomes directly, so nobody should claim the data proves function is preserved either. What we can say, sourced to what was actually measured: the fat-to-lean ratio on a GLP-1 looks similar to intentional weight loss generally, and it isn't zero lean-mass loss.

The one lever the evidence-adjacent literature agrees on

Resistance training and adequate protein intake during any significant weight loss — GLP-1-assisted or not — are the standard clinical recommendations for preserving lean mass, and neither trial above tested or reported on participants' exercise or protein habits as a variable, so this isn't something the cited studies proved works specifically on a GLP-1. It's a general principle carried over from the broader weight-management literature, worth raising with your prescriber rather than treating this article as complete guidance on its own.

Where this fits your provider decision

A program that only tracks the number on the scale isn't giving you the full picture of what's changing in your body. Ask whether your provider discusses body composition, not just total weight, as part of ongoing care — see how we weigh medical substance over marketing in our Value Score methodology. Side effects and muscle loss aren't the only trade-offs worth understanding before you start; see the full adverse-event breakdown in GLP-1 side effects: what the STEP and SURMOUNT trials actually reported, and how titration pace affects tolerability in GLP-1 dosing and titration: how the schedule actually works.

Comparing programs

Compare pricing and prescriber quality across verified programs on our semaglutide and tirzepatide boards, and read the medical-oversight notes in our provider reviews.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.